Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tofacitinib Citrate
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TWi Biotechnology Exploring Promising Treatment for Granuloma Annulare (GA)
Details : AC-1101 (tofacitinib) topical gel phase I study patients with granuloma annulare. The oral formulation of tofacitinib has already been FDA approved to treat such ailments as rheumatoid arthritis.
Product Name : AC-1101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 06, 2023
Lead Product(s) : Tofacitinib Citrate
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diacerein
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Hong Kong Winhealth Pharma Group
Deal Size : Undisclosed
Deal Type : Partnership
Winhealth Pharma and TWiB Enter into Strategic Licensing Partnership on AC-203
Details : Strategic partnership grants Winhealth Pharma exclusive right to develop and commercialize rare disease asset AC-203 in mainland China, Hong Kong and Macao for indications including hereditary epidermolysis bullosa (EB), bullous pemphigoid and other skin...
Product Name : AC-203
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 01, 2021
Lead Product(s) : Diacerein
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Hong Kong Winhealth Pharma Group
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Tofacitinib Citrate
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TWiB Receives Canada Health Approval for AC-1101 Phase 1 CTA
Details : Health Canada has approved Ancheng Biotech's open-label, fixed-sequence, two-period, comparative bioavailability study of AC-1101 (Tofacitinib Citrate). Tofacitinib Citrate is a topical JAK inhibitor for the treatment of vitiligo.
Product Name : AC-1101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 05, 2020
Lead Product(s) : Tofacitinib Citrate
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable